metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Use of Bladder Epicheck® in the follow-up of non-muscle-invasive Bladder cancer...
Journal Information
Vol. 48. Issue 8.
Pages 555-564 (October 2024)
Share
Share
Download PDF
More article options
Visits
3
Vol. 48. Issue 8.
Pages 555-564 (October 2024)
Review article
Use of Bladder Epicheck® in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review
Utilidad de Bladder Epicheck® en el seguimiento del tumor de vejiga no músculo infiltrante: revisión sistemática de la literatura
Visits
3
J. Caño Velascoa,
Corresponding author
jorge.cano@salud.madrid.org

Corresponding author.
, S. Artero Fullanaa, L. Polanco Pujola, A. Lafuente Puenteduraa, J.D. Subielab, J. Aragón Chamizoa, M. Moralejo Gáratea, C. Hernández Fernándeza
a Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Servicio de Urología, Hospital Universitario Ramón y Cajal, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (1)
Table 1. Systematic review of the literature on the value of Bladder Epicheck® during the follow-up of NMIBC.
Abstract
Introduction

In recent years, different urinary markers such as the Bladder Epicheck® have been developed in an attempt to reduce the number of cystoscopies in the follow-up of non-muscle invasive bladder cancer (NMIBC).

Aim

To provide a systematic review of Bladder Epicheck® and its current clinical utility in the follow-up and detection of recurrence of NMIBC.

Material and methods

Systematic review based on a literature search of PubMed, Web of Science and Scopus databases until October 2023, according to PRISMA and Quadas-2 criteria. Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of the marker were calculated. Diagnostic performance was evaluated by the area under the curve (AUC).

Results

Fifteen studies were analyzed (n = 3761) including 86.7% prospective studies. Of the patient series, 53.2% had received previous intravesical instillations. The mean Se of the biomarker in the detection of recurrence varied according to tumor grade (87.9%-high grade/HG vs. 44.9%-low grade/LG, respectively). Their weighted mean Se and Sp were 71.6% and 84.5%, respectively. The mean recurrence rate was 29.1%. The weighted mean PPV and NPV were 56.4% and 92.8% (97.7% non-LG), respectively. The mean AUC was 85.63%.

Conclusion

Bladder Epicheck® is a useful urinary marker in the follow-up of NMIBC, with significantly high Se and NPV in the detection of recurrences, especially in cases of HG disease. Its use can reduce the number of cystoscopies required in the follow-up of NMIBC, improving the quality of life of patients and potentially increasing health economic savings.

Keywords:
Bladder cancer
Urinary biomarker
Bladder Epicheck®
Follow-up
Cystoscopy
Resumen
Introducción

En los últimos años se han desarrollado diferentes biomarcadores urinarios,entre ellos Bladder Epicheck®,con el fin de disminuir el número de cistoscopias en el seguimiento de los tumores vesicales no músculo infiltrantes(TVNMI).

Objetivo

Proporcionar una revisión sistemática sobre Bladder Epicheck® y su aplicabilidad clínica actual en el seguimiento y detección de recurrencia de los TVNMI.

Material y métodos

Revisión sistemática basada en la búsqueda bibliográfica a través de PubMed, Web of Science y Scopus hasta octubre de 2023, acorde a los criterios PRISMA y Quadas-2. Se calcularon la sensibilidad(S), especificidad(E) y valores predictivos positivo(VPP) y negativo(VPN) del biomarcador. El rendimiento diagnóstico se evaluó mediante el área bajo la curva(AUC).

Resultados

Se analizan 15 estudios(n = 3761), siendo el 86,7% prospectivos. El 53,2% de la serie había recibido instilaciones intravesicales previas. La S media del biomarcador en la detección de recurrencia varió según el grado tumoral(87,9%-alto grado (high grade/HG) vs 44,9%-bajo grado(low grade/LG, respectivamente). Su S y E media ponderada fue del 71,6% y 84,5%, respectivamente. La tasa media de recidivas fue del 29.1%. Los VPP y VPN medios ponderados fueron de 56,4% y 92,8% (97,7% no-LG), respectivamente. El AUC medio fue del 85.63%.

Conclusión

Bladder Epicheck® es un biomarcador urinario útil en el seguimiento de los TVNMI, destacando su elevada S y VPN en la detección de recurrencias, sobre todo en casos de HG.Su uso puede reducir el número de cistoscopias necesarias a realizar en dicho seguimiento, mejorando la calidad de vida de los pacientes y con un probable impacto en el ahorro económico sanitario.

Palabras clave:
Cáncer de vejiga
Biomarcador urinario
Bladder Epicheck®
Seguimiento
Cistoscopia

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos